Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
[If she alters the split reducing wamuqs percent down from 30% wouldn't that change the agreed settlement of the dimes which agreed to the 8.xx% of the 30% ... isn't it written as such? /quote]
I know. I know. Raising my hand after reading posts about bankruptcy for three long years. The court can approve the same agreement or improvements in settlements without court authorization. Back to lurking with Lebosco.
Here I am in fla without a computer and this crazy iPhone. Are people talking about the Reuters article class action settlement? 12 min ago. Can't even post link. Or is it s head fake? Arghhh
Ilene is being quoted!!! Have you been interviewed by Bloomberg? I think I remember reading a similar post by you last night. Way to go Ilene...you are gaining status daily. Of course we all knew that. What a wild ride this is.
“It’s bad for shareholders unless it is a temporary collapse,” Ilene Slatko, a WaMu common shareholder who also covers the case through Twitter for her company, Delaware Shareholder Services. “I’d like to believe that whatever information the committee has will be enough to stop the sixth plan.”
Yep. Been here all along. Waiting and waiting. Hopefully today our day! GLTU
http://www.barchart.com/quotes/stocks/WAMUQ
2nd Resistance Point 0.1110
1st Resistance Point 0.0950
Last Price 0.0790
1st Support Level 0.0520
2nd Support Level 0.0250
I find barchart to be pretty reliable. Friday 2nd resistance point was .094 and changed to strong buy.
necktoeye I have no idea what you are talking about but your post is incredibly interesting. GLTA
I want to believe there is some magic here. The volume was low on the clip and I was forced to watch his body language, sighs before the speech. indirect gaze and pauses. It was not a picture of confidence. Having said that, I hope you are right and I am wrong
Add me to the list that totally agree with your statements regarding THJMW.
That makes perfect sense, Locks
I don't know about Locks but I believe that there are some smart people on the board. Surely everyone realizes that if a company is clean and gives benefits to individuals for travel etc. they of course have to claim as income. hmmm must be expensive to go to China, for example.
It is illegal to "discriminate" against a patient based on their ability to pay for services. Health care organizations have to develop one standard to treat patients and that is guidlines and reimbursement by Medicare/Medicaid. The insurance companies know a good deal when they see one so set up the same standards. That way everyone is in compliance.
I have seen very few cases of discrimination based on ability to pay over the years. It may happen more frequently in the future based on the major crunch going on in health care but it would never be labeled as such. I have seen many cases of MD reluctance to prescribe therapy based on a family's ability and/or willingness to comply with treatment. If someone has transportation problem or is not reliable in getting prescription filled, that fact may play a role in prescribing treatment. OR if a treatment could cure someone but their immune system is such that they would die in the process, obviously that's not the way to go. Also let's remember that a heart attact is not a heart attack & prostrate cancer comes in many stages and conditions. There are many forms of each disease and often how the disease plays itself out depends on the person's pre-existing health. It is all very complex stuff which makes it impossible for anyone to make a judgement about whether one person received priority care over another person without significant DD by a medical professional. Even then it is debatable as we all know in med mal.
Anyway, hope to see green today!
I imagine the attorneys involved would get the ruling before it's posted on Pacer, right? I thought I read somewhere a day or days. Does anyone know how that time sequence works?
quote..."you can look for my ruling... IN THE MORNING...on all of the matters"
Merry Christmas to all on the board and a healthy, Happy New year!
Have I missed the document or filing from CCEL on this board? I know that KKCEL posts some lawsuits but this appears to be local, small claims court stuff maybe? If someone has the info, would appreciate.
If true, that would be sweet. RE a cash business. I like it.
Thanks for the link. I have thought all along that the bottom line on this case resides with Paulson's actions during the height of the recession. Good to see some media attention.
Thanks. He did a lot of work on that one. Nice to see you back.
Great summary. Wonder if the mods would sticky.
Time for an infomercial:
http://learn.genetics.utah.edu/content/tech/stemcells/sctoday/
I would encourage you to look at the full link as pictures are awesome. As a Pediatric Hematologist/Oncologist colleague explained to me stem cell therapy suffers from confusion related to the words stem cell as there are many types of stem cells in the process of the body making blood as well as umbilical cells, transplants etc. Regardless, what is considered useful for bone marrow transplant is also considered applicable to the other "products" used in transplant therapy. Often the expressions are used interchangeably because the utility is so closely related. So while you are technically correct that bone marrow transplants are not umbilical cell transplants they are indeed related and the article does have relevance.
STEM CELL THERAPIES TODAY
Did you know that several stem cell therapies are routinely used to treat disease today?
These include:
¦Adult Stem Cell Transplant: Bone Marrow Stem Cells
¦Adult Stem Cell Transplant: Peripheral Blood Stem Cells
¦Umbilical Cord Blood Stem Cell Transplant
Adult Stem Cell Transplant: Bone Marrow Stem Cells
Perhaps the best-known stem cell therapy to date is the bone marrow transplant, which is used to treat leukemia and other types of cancer, as well as various blood disorders.
Why is this a stem cell therapy?
Leukemia is a cancer of white blood cells, or leukocytes. Like other blood cells, leukocytes are made in the bone marrow through a process that begins with multipotent adult stem cells. Mature leukocytes are released into the bloodstream, where they work to fight off infections in our bodies.
Leukemia results when leukocytes begin to grow and function abnormally, becoming cancerous. These abnormal cells cannot fight off infection, and they interfere with the functions of other organs.
Successful treatment for leukemia depends on getting rid of all the abnormal leukocytes in the patient, allowing healthy ones to grow in their place. One way to do this is through chemotherapy, which uses potent drugs to target and kill the abnormal cells. When chemotherapy alone can't eliminate them all, physicians sometimes turn to bone marrow transplants.
In a bone marrow transplant, the patient's bone marrow stem cells are replaced with those from a healthy, matching donor. To do this, all of the patient's existing bone marrow and abnormal leukocytes are first killed using a combination of chemotherapy and radiation. Next, a sample of donor bone marrow containing healthy stem cells is introduced into the patient's bloodstream.
If the transplant is successful, the stem cells will migrate into the patient's bone marrow and begin producing new, healthy leukocytes to replace the abnormal cells.
Adult Stem Cell Transplant: Peripheral Blood Stem Cell Transplant
While most blood stem cells reside in the bone marrow, a small number are present in the bloodstream. These multipotent peripheral blood stem cells, or PBSCs, can be used just like bone marrow stem cells to treat leukemia, other cancers and various blood disorders. Since they can be obtained from drawn blood, PBSCs are easier to collect than bone marrow stem cells, which must be extracted from within bones. This makes PBSCs a less invasive treatment option than bone marrow stem cells. PBSCs are sparse in the bloodstream, however, so collecting enough to perform a transplant can pose a challenge.
Umbilical Cord Blood Stem Cell Transplant
Newborn infants no longer need their umbilical cords, so they have traditionally been discarded as a by-product of the birth process. In recent years, however, the multipotent-stem-cell-rich blood found in the umbilical cord has proven useful in treating the same types of health problems as those treated using bone marrow stem cells and PBSCs.
Umbilical cord blood stem cell transplants are less prone to rejection than either bone marrow or peripheral blood stem cells. This is probably because the cells have not yet developed the features that can be recognized and attacked by the recipient's immune system. Also, because umbilical cord blood lacks well-developed immune cells, there is less chance that the transplanted cells will attack the recipient's body, a problem called graft versus host disease.
Both the versatility and availability of umbilical cord blood stem cells makes them a potent resource for transplant therapies.
IDK chaarles, I read the article and was somehow able to get past the first few paragraphs which was no small feat lol. If you read between the lines I think the author is saying that Dimon epitomizes what America hates the most about big banks and he is not infallible. Could be a little tongue in cheek commentary. The last statement or so reminds us that past performance is no guarantee for future performance. It was worth reading to the end for that one! Thanks for sharing.
After all these months of watching THJMW rule, it can mean only one thing IMO...delay, delay, delay. Maybe ok at this point. Have enjoyed your posts recently Chiron. Great sense of humor.
Why allow shareholders to speak after closing arguments?
One more thank you and Happy Birthday, Ilenes. Incredible courage to ask to speak to the court. I'm sure when the time comes you will speak from the heart and deliver a powerful message. I have a feeling this will be an incredible year for you!!!
Great find. I wonder if the conflict of interest stated has anything to do with the recent slew of attorneys being admitted to the case. I would think the firm still would have a conflict but I don't know for sure.
Wow. Hard to believe. Thanks for the info.
I'm trying to remember if 788 is up or down from the early objections to the Spring POR. Do you know? So many filings/so little time. GLTU/A
Good morning all. I have read all recent posts with interest. IMO it is important to realize that anything significant related to cancer therapy with cord blood in this country will be through a Clinical Trial supported by the NCI. Many types of leukemia are curable through a variety of treatments besides cord blood. I believe the case reported today was unique in that traditional therapies had been tried and cord blood was the last option. Cures reported from other countries are published in international literature and then US and other scientists may adapt the concepts or try to get funding for clinical trials. This doesn't mean the US is the expert but US science is very precise and accurate, conservative. Cancer treatment is a very safe (some may say boring) and highly regulated process in this country. The fact that CBAI is established internationally is huge in that respect as it leaves us with many options until the US gets on board. I wish I knew more about the process for cancer therapy in countries where cord blood storage banks are located.
I wanted to offer a very basic slide show from the National Cancer Institute which may be a review to many. The case for public or public/private storage is illustrated as well.
http://www.cancer.gov/cancertopics/understandingcancer/StemCells/Slide24
I kind of remember you saying that but to me it is all about folks filtering in and out of this investment to demonstrate the interest. Ilenes totally beyond reproach.
ilenes you are back. You have been missed by many on the board!
Great post Jest. I agree that there is an elephant on the table. Question is what the elephant looks like NOT under seal. GLTU/A
your post reminded me of something I read recently. I know people on the board don't like to discuss any similarity between lehman and Washington Mutual. I did find this article interesting.
kind of explains the "run" on the bank too... just who did pull all that money from wamu and who clued them in as to what was about to go down?
Holter I'm not sure of the source of the original publication so can only speculate in response to your question. My interpretation is that the process of skin cell harvesting was put on hold because another lab storage contract was needed. I can't say whether or not that pertains to the Vegas facility or another facility. Not much help.
With all due respect daisy, please tell your colleagues that's the biggest sexist remark I've ever heard and I've heard a lot. Being sexist is not about just categorizing women in a sexual role. I would never be associated with your firm even if you are joking is my opinion.
Now that's an interesting post. thanks for sharing.
Don when you initiated the United connection I could not help but think that you have incredible "fight" in you. When one door closes, you figure out another door to open. And reach out to all of us in the process. All I can say is, you must have been an incredible asset to our country while in the service. AND that now is the time to reserve the "fight" to your internal healing powers. I'm sure everyone on this board will agree that you can accomplish, no problem. Thanks for all you do for the board.
Kurtzberg answered the question about using a child's own cells later in the article. I think she is just saying one size doesn't fit all. Not meant to be as broad as private umbilical cell storage not a good thing. If you read the article closely you will see that the opinions expressed are those of multiple physicians not Kurtzman only. It is hard to follow who says what in that respect.
For example, if a child develops leukemia, there are usually leukemia cells in the cord blood, making them inappropriate for a transplant, transplant experts say. Or if a child has a genetic disorder, such as sickle cell, that same problematic DNA lies in the cord blood cells, rendering them useless.
Kurtzberg says she is using children's own cord blood cells experimentally to see if they can help treat cerebral palsy or brain damage caused by low oxygen at birth.
"We're in the middle of our study, so we don't know yet if it works," she says.
Thanks Rumble. Agree fav part
OK so I had a CBAI moment today that I wanted to share. I work in a hospital and have many friends around the building, some of whom have been former patients or parents of patients. One of my friends in the cafeteria stopped me and said she wanted to ask me about a card she got in the mail for the umbilical cord test. Her daughter is about 23 and she has progressively worsening sickle cell anemia. She said that the letter she received said it was a new treatment and her daughter may qualify. As I understand it umbilical cord cell transplant is not for everyone with sickle cell anemia. The benefits have to outweigh the risks. In her daughter's case, she has been in the hospital frequently and it is difficult to keep a job or live a normal life. So on the surface, she could be a good candidate for a umbiical cord cell transplant. It's impressive that the word is getting out to people who really need the help. All around good CBAI day for me!
Here ya go.
StemCells, Inc. Files to Conduct Neural Stem Cell Trial in Chronic Spinal Cord InjuryBY GlobeNewswire
— 8:00 AM ET 11/15/2010
PALO ALTO, Calif., Nov. 15, 2010 (GLOBE NEWSWIRE) -- StemCells, Inc. (STEM) announced today that is has filed an application with Swissmedic, the Swiss regulatory agency for therapeutic products, to conduct a clinical trial in Switzerland of the Company's HuCNS-SC(R) purified human neural stem cells in chronic spinal cord injury patients. If authorized, the study would enroll patients who are three to 12 months post-injury.
"With this filing we have taken a tangible step to broaden the clinical development of our HuCNS-SC product candidate beyond the brain and into the spinal cord," said Martin McGlynn, President and CEO of StemCells, Inc. (STEM) "This exciting initiative is supported by extensive preclinical research demonstrating the ability of our proprietary cells to restore lost motor function when transplanted in the chronic spinal cord injury setting. The prospect of extending the treatment window to months or longer following injury would mean that a much larger population of injured patients could potentially benefit from such an approach."
Stephen Huhn, MD, FACS, FAAP, Vice President and Head of the CNS Program at StemCells, Inc. (STEM), added, "Switzerland is home to some of the leading clinicians and medical centers in the world engaged in the treatment and rehabilitation of spinal cord injury patients, which makes it an excellent setting for this type of trial. While we have yet to secure Swissmedic authorization to initiate the study, we are pleased to have already received approval from the respective ethics committees at our anticipated trial site and the local Canton, both of which are prerequisites for making a submission of this kind in Switzerland."
The results of numerous collaborative preclinical studies with researchers at the University of California, Irvine (UCI) demonstrate the significant therapeutic potential of the Company's human neural stem cells for the treatment of spinal cord injury. Data published in several peer-reviewed journals show that the cells engraft, migrate along the spinal cord to the point of injury, and then differentiate into neurons and specialized cells called oligodendrocytes that create the insulation (myelin) necessary for proper transmission of nerve impulses from the brain to below the level of injury. When transplanted in spinal cord-injured mice at both sub-acute and chronic injury time points, the cells have been shown to form protective myelin sheaths around damaged nerve axons and enable a significant and persistent recovery of walking ability.
Aileen Anderson, Ph.D., Associate Professor in the Departments of Physical Medicine and Rehabilitation, and Anatomy and Neurobiology at UCI, commented, "The preclinical data we have seen to date provide a compelling rationale for advancing these neural stem cells into clinical testing for chronic spinal cord injury. Restoring some degree of function for patients at later time points beyond the acute injury phase could have a transformative impact on the field as there are no effective treatment options for them today. The demonstrated ability of these cells to repair an injured spinal cord and promote functional motor recovery in animals could translate into improved quality of life for individuals living with paralysis, and I am excited to see StemCells (STEM) take this important next step toward what I hope will one day become a viable therapy for a broad population of spinal cord-injured patients."
About Chronic Spinal Cord Injury
According to a recent study initiated by the Christopher and Dana Reeve Foundation, nearly 1.3 million people in the U.S. alone are estimated to be living with chronic spinal cord injury. Chronic spinal cord injury is characterized as a point in time after injury in which inflammation has stabilized and behavioral recovery has reached a plateau. In spinal cord-injured patients, the chronic phase typically does not set in until several weeks or months following the injury. To date, treatment approaches have generally targeted the acute and sub-acute time points post-injury, which are considered to be hours or days following injury. StemCells (STEM) hopes to address a broader population of spinal cord-injured patients by opening the window of opportunity for therapeutic intervention to months or longer post-injury.
More information about the Company's spinal cord injury program can be found on the StemCells, Inc. (STEM) website at http://www.stemcellsinc.com/Therapeutic-Programs/Spinal-Cord-Injury.htm, including video interviews with Drs. Stephen Huhn and Aileen Anderson, as well as Irving Weissman, MD, Chair of the Scientific Advisory Board and Director, StemCells, Inc. (STEM)
You may have already posted this. Sounds similar to previous post but can't exactly find it now.
http://www.prnewswire.com/news-releases/lyophilized-heparin-preserves-cord-blood-stem-cells-better-than-commonly-used-anticoagulant-citrate-phosphate-dextrose-94818924.html
cici Ok... he is consistent in his postings throughout this experience and a long if you think outside the box a bit. GLTU
I'm pretty sure I know the answer to this question which would be YES although there may be a period of time that a few flagrant souls may spread their wings. Red Cross the ultimate safe haven for patient safety and advocacy. The "big Picture" it is.
http://www.redcross.org/